Lv21
126 积分 2022-10-30 加入
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
1小时前
已完结
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
9小时前
已关闭
Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
9小时前
已完结
Pan-cancer single-cell landscape of tumor-infiltrating T cells
6天前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
2个月前
已关闭
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
4个月前
已完结
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma
8个月前
已完结
Epigenetics in advanced renal cell carcinoma: Potential new targets
8个月前
已完结
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
8个月前
已完结
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials
9个月前
已完结
皖公网安备34019202002308
